Tagged Articles

cancer risks 45 articles

Diabetes drug tested as treatment for non-alcoholic fatty liver disease

Researchers are testing type 2 diabetes drug Victoza as a possible treatment for non-alcoholic fatty liver disease, the most common form of liver disease in the United States, affecting about 20 percent of the population. The condition describes a wide range of conditions that are caused when fat builds up within the liver. Non-alcoholic steathohepatitis, or NASH, is the most serious form of the disease, and can lead to total liver failure requiring liver transplant. NASH is known as a silent killer because it does not present with many symptoms and those affected generally feel well. Risk factors include obesity, ... Read More

Attorneys request consolidation of power morcellator lawsuits

Attorneys for six women suing Johnson & Johnson over injuries they claim to have suffered after undergoing gynecological procedures with the company’s power morcellator device have filed a request with the U.S. Judicial Panel on Multidistrict Litigation to consolidate with at least 22 similar lawsuits pending in 16 different federal district courts. The motion seeks to transfer the cases to U.S. District Judge Kathryn Vratil in Kansas. The request comes just weeks after the Wall Street Journal reported that Johnson & Johnson was being investigated by the Federal Bureau of Investigation (FBI) about how much the company knew about cancer ... Read More

Heart health concerns lead to more studies of newer type 2 diabetes drugs

Safety concerns with newer type 2 diabetes medications has prompted a new study into cardiovascular risks in patients who use the drugs. Earlier this month, a Food and Drug Administration (FDA) advisory panel recommended that two new diabetes drugs, Onglyza and Nesina, include new information about the risk of heart failure. The drugs are in a class of medications known as incretin mimetics, which includes the brand name diabetes drugs Victoza, Byetta and Januvia. Onglyza and Nesnia share a subclass known as DPP-4 inhibitors with Januvia, and this prompted researchers to take a closer look at cardiovascular risks with Januvia. ... Read More

Lawsuit claims Johnson & Johnson should have warned consumers about ovarian cancer risk with baby powder

A woman suing consumer health care giant Johnson & Johnson alleging the company should have included ovarian cancer warnings on its baby powder says it is irrelevant that she never developed the disease; she still suffered financial injury from buying the product under false pretenses year after year. Plaintiff Barbara Mihalich’s response was aimed at Johnson & Johnson’s motion to dismiss her case and mischaracterize her claims as a personal injury lawsuit. Mihalich claims that she –and other women like her – would likely have never purchased the product had they known the powder could increase their risk of developing ... Read More

Plaintiff claims Actos bladder cancer warnings were not strong enough to convey risks

Takeda Pharmaceutical Co., attempted to convince a Philadelphia jury that it adequately warned of bladder cancer risks on the label of its type 2 diabetes drug Actos by presenting testimony from a former senior official with the Food and Drug Administration (FDA) David Feigal Jr., an expert witness for the drug company, said that Takeda had funded several studies to gauge the cancer risks with its once-blockbuster drug and had included that information on the drug’s insert. However, plaintiff Frances Wisniewski claims differently. She took Actos for seven years and developed tumors in her bladder. Her lawsuit alleges that Takeda ... Read More

Controlling blood sugar does not prevent heart attacks, strokes, death

People with type 2 diabetes can protect themselves against heart attacks, strokes and death by intensively lowering their blood pressure, but intensive blood sugar control did not produce the same benefits, according to new research published in the New England Journal of Medicine. The study involved nearly 8,500 participants who had completed a diabetes trial during which some patients had their blood pressure and blood sugar levels strictly controlled, and others received standard care. The diabetes trial had shown a clear benefit from blood pressure reduction and blood sugar lowering. However, the unanswered question was whether the benefits go away or ... Read More

Artificial sweeteners may increase the risk of type 2 diabetes

Using artificial sweeteners may disrupt the way the body handles sugar, increasing the risk of diabetes for some people, according to a new study published in the journal Nature. The research, conducted primarily on laboratory animals, suggests that artificial sweeteners, such as Splenda, Equal and NutraSweet, can change the bacteria that normally resides in the gut. When this happens, it disrupts how the body handles sugar in the diet, which can lead to increased blood sugar levels, a condition called glucose intolerance, which is a precursor to type 2 diabetes. Researchers say that it is too early to caution people ... Read More

FDA panel recommends approving diabetes treatment for obese patients

A Food and Drug Administration (FDA) advisory panel has given a thumbs-up recommendation to Novo Nordisk’s type 2 diabetes drug liraglutide for the treatment of chronic obesity in patients with at least one weight-related health issue, such as hypertension or pre-diabetes. Liraglutide, known commercially as Victoza, would be sold under the label Saxenda for the obesity indication if it is approved by the FDA. The agency is not required to follow the recommendations of its advisory panels, but it usually does. The positive recommendation was based on a clinical trial in which patients were given 3 mg of liraglutide. About ... Read More

New diabetes research center opens at University of Iowa

The University of Iowa has opened a new Diabetes Research Center dedicated to finding treatments and cures for diabetes. “The goal ultimately is to really help the University of Iowa become a major hub for cutting-edge diabetes research that will really capture the attention of the world,” said Dr. E. Dale Abel, the center’s director. Researchers at the university have been working various pilot projects in the past three years, including research on glucose production, natural treatments for diabetic nerve disease, and experimental drugs such as FGF21, which has been shown to have beneficial effects on lipid, body weight and ... Read More

Drug companies fight request for more information linking diabetes drugs to pancreatic cancer

A number of drug companies are fighting a request to produce documents involving reports linking pancreatic cancer to use of their type 2 diabetes treatments. Defendants Merck Sharp & Dohme Corp., Eli Lilly, Novo Nordisk, and Amylin Pharmaceuticals told a California federal court that gathering the requested information would be an “unreasonably burdensome fishing expedition.” Plaintiffs already have adverse events reports but are now seeking source files including underlying medical records of individual patients used to compile the reports. The motion is the most recent development in a multidistrict litigation against the drug companies that manufacture and distribute a newer ... Read More